{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:59:00Z","timestamp":1773806340302,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105413","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:58:51Z","timestamp":1773802731000},"source":"Crossref","is-referenced-by-count":0,"title":["Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution"],"prefix":"10.7759","author":[{"given":"Christopher M","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rae-Anne","family":"Kastle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Zargarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmeen","family":"Sawalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Dalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell PJ","year":"2006","unstructured":"Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006, 355:2452-66. 10.1056\/NEJMra063728","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino BK","year":"2018","unstructured":"Marcellino BK, Hoffman R, Tripodi J, et al.. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018, 2:3581-9. 10.1182\/bloodadvances.2018024018","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi A","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, et al.. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013, 27:1874-81. 10.1038\/leu.2013.163","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti F","year":"2008","unstructured":"Passamonti F, Rumi E, Caramella M, et al.. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008, 111:3383-7. 10.1182\/blood-2007-11-121434","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002271","article-title":"Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation","volume":"4","author":"Luque Paz D","year":"2020","unstructured":"Luque Paz D, Jouanneau-Courville R, Riou J, et al.. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020, 4:4887-97. 10.1182\/bloodadvances.2020002271","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld J","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, et al.. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018, 379:1416-30. 10.1056\/NEJMoa1716614","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169023","article-title":"KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives","volume":"25","author":"Guarnera L","year":"2024","unstructured":"Guarnera L, D'Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int J Mol Sci. 2024, 25:9023. 10.3390\/ijms25169023","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama A","year":"2005","unstructured":"Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005, 123:207-18. 10.1016\/j.cell.2005.09.025","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar AJ","year":"2020","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020, 136:61-70. 10.1182\/blood.2019000943","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092378","article-title":"Genetic characteristics according to subgroup of acute myeloid leukemia with myelodysplasia-related changes","volume":"11","author":"Kang D","year":"2022","unstructured":"Kang D, Jung J, Park S, et al.. Genetic characteristics according to subgroup of acute myeloid leukemia with myelodysplasia-related changes. J Clin Med. 2022, 11:2378. 10.3390\/jcm11092378","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01200-4","article-title":"Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy","volume":"9","author":"Huang W","year":"2025","unstructured":"Huang W, Zhang F, Zhang Z, Wang Q, Chen S. Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy. NPJ Precis Oncol. 2025, 9:396. 10.1038\/s41698-025-01200-4","journal-title":"NPJ Precis Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104783","article-title":"Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review of safety and efficacy","volume":"213","author":"Dali SA","year":"2025","unstructured":"Dali SA, Al-Mashdali AF, Kalfah A, Mohamed SF. Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review of safety and efficacy. Crit Rev Oncol Hematol. 2025, 213:104783. 10.1016\/j.critrevonc.2025.104783","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315256","article-title":"Novel molecular insights into leukemic evolution of myeloproliferative neoplasms: a single cell perspective","volume":"23","author":"Rontauroli S","year":"2022","unstructured":"Rontauroli S, Carretta C, Parenti S, Bertesi M, Manfredini R. Novel molecular insights into leukemic evolution of myeloproliferative neoplasms: a single cell perspective. Int J Mol Sci. 2022, 23:15256. 10.3390\/ijms232315256","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch C","year":"2003","unstructured":"Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003, 102:2395-402. 10.1182\/blood-2003-02-0434","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer C","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, et al.. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023, 37:988-1005. 10.1038\/s41375-023-01877-1","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.16.5678-5687.2001","article-title":"The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis","volume":"21","author":"Luo RT","year":"2001","unstructured":"Luo RT, Lavau C, Du C, Simone F, Polak PE, Kawamata S, Thirman MJ. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol. 2001, 21:5678-87. 10.1128\/MCB.21.16.5678-5687.2001","journal-title":"Mol Cell Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2a-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa GC","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al.. Menin inhibition with revumenib for KMT2a-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025, 43:75-84. 10.1200\/JCO.24.00826","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026232","article-title":"Menin inhibitors in the treatment of acute myeloid leukemia","volume":"145","author":"Huls G","year":"2025","unstructured":"Huls G, Woolthuis CM, Schuringa JJ. Menin inhibitors in the treatment of acute myeloid leukemia. Blood. 2025, 145:561-6. 10.1182\/blood.2024026232","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27583","article-title":"Maintenance therapy in AML: what is the future potential?","volume":"100 Suppl 2","author":"Goulart H","year":"2025","unstructured":"Goulart H, Wei AH, Kadia TM. Maintenance therapy in AML: what is the future potential?. Am J Hematol. 2025, 100 Suppl 2:38-49. 10.1002\/ajh.27583","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35332","article-title":"Targeting the menin-KMT2A interaction in leukemia: Lessons learned and future directions","volume":"158","author":"Perner F","year":"2026","unstructured":"Perner F, Gadrey JY, Armstrong SA, K\u00fchn MW. Targeting the menin-KMT2A interaction in leukemia: Lessons learned and future directions. Int J Cancer. 2026, 158:342-56. 10.1002\/ijc.35332","journal-title":"Int J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470966-sequential-transformation-of-polycythemia-vera-to-myelofibrosis-and-kmt2a-rearranged-acute-myeloid-leukemia-treated-with-revumenib-a-rare-case-of-clonal-evolution","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:58:52Z","timestamp":1773802732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470966-sequential-transformation-of-polycythemia-vera-to-myelofibrosis-and-kmt2a-rearranged-acute-myeloid-leukemia-treated-with-revumenib-a-rare-case-of-clonal-evolution"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.105413","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}